A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Phase 1 – testing safety in a small group of people
Conditions:
Lymphoma, Non-Hodgkin's
Lymphoma, Diffuse Large B-Cell
Follicular Lymphoma
Sponsor: Eli Lilly and Company
trial.available_in:
БГ
Overview
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
Who can participate
Inclusion Criteria:
* Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy:
* Diffuse large B-cell lymphoma - not otherwise specified
* High-grade B-cell lymphoma
* Follicular large B-cell lymphoma
* Follicular lymphoma
* Other non-Hodgkin lymphoma
* Has measurable disease
* Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy
Exclusion Criteria:
* Has an active second cancer
* Has known or suspected history of central nervous system involvement
* Has known Cytomegalovirus infection. Participants with negative status are eligible
* Has known hepatitis B or C infection or HIV
* Has significant heart disease
Interventions
LY4584180
DRUG
Rituximab
DRUG
Locations
45
France (5)
CHU de Nantes - Hotel-Dieu
Nantes
Institut Curie
Paris
CHU Bordeaux - Hopital Haut-Leveque - Centre Francois Magendie
Pessac
HCL Centre Hospitalier Lyon Sud
Pierre-Bénite
Oncopole Claudius Regaud
Toulouse
Germany (4)
Charite Universitaetsmedizin Berlin
Berlin
Universitaetsklinikum Koeln (AoeR)
Cologne
Universitaetsklinikum Essen
Essen
Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet
Frankfurt am Main
Italy (2)
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola
Bologna
Istituto Europeo di Oncologia
Milan
Japan (2)
National Cancer Center Hospital East
Chiba
Cancer Institute Hospital of JFCR
Tokyo
Poland (4)
Pratia Onkologia Katowice
Katowice
Pratia MCM Krakow
Krakow
AIDPORT Sp. z o.o.
Skorzewo
Instytut Hematologii i Transfuzjologii w Warszawie
Warsaw
Spain (2)
Institut Catala d'Oncologia - L'Hospitalet
Barcelona
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
Madrid
United Kingdom (5)
King's College Hospital
London
The Royal Marsden NHS Foundation Trust
London
Nottingham City Hospital
Nottingham
Derriford Hospital
Plymouth
University Hospital Southampton NHS Foundation Trust
Southampton
United States (21)
Emory University Hospital
Atlanta , Georgia
Massachusetts General Hospital
Boston , Massachusetts
Dana-Farber Cancer Institute
Boston , Massachusetts
The Ohio State University (OSU)
Columbus , Ohio
Texas Oncology - DFW (Sammons CC)
Dallas , Texas
Colorado Blood Cancer Institute
Denver , Colorado
City of Hope
Duarte , California
Baylor College of Medicine
Houston , Texas
University of California, Los Angeles (UCLA) - Medical Center
Los Angeles , California
University of Miami - Sylvester Cancer Center
Miami , Florida
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee , Wisconsin
Sarah Cannon Research Institute
Nashville , Tennessee
Vanderbilt University Medical Center
Nashville , Tennessee
Columbia University
New York , New York
Oregon Health & Science University (OHSU)
Portland , Oregon
Mayo Clinic - Rochester
Rochester , Minnesota
University of Rochester
Rochester , New York
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center
San Francisco , California
Florida Cancer Specialists - Sarasota
Sarasota , Florida
Mayo Clinic - Scottsdale
Scottsdale , Arizona
University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance)
БГ